Attana enters the third year of a five-year service and support contract with a leading health institute in the US

The contract is now entering its third year and it is an important part of the company's plan to establish strong reference customers in the US. During the past year, several users have been trained in Attana's technology, and studies of T-cell interactions with animal cancer cells are currently being performed. The intention is that the data from the experiments will be published at the end of this year and that the project will then also be carried out on tumor tissues from biopsies.

The institute is an important part in establishing strong reference customers in the USA. The projects are chosen so that, upon completion, they will clearly highlight the advantages and value creation of Attana technology compared to traditional methods. Since the experiments with the institute go hand in hand with clinical studies and animal experiments, the project runs for a total of five years and is now about halfway through.

For more information, please contact:

Teodor Aastrup, CEO
ir@attana.com
+46 708 86 23 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com